[1] |
郑天宇, 黄飚, 周秀梅. PLA2R抗原表位及其抗体在特发性膜性肾病中的研究进展[J]. 中国细胞生物学学报, 2022, 44(6):1211-1218.
|
[2] |
邢会霞, 姜泽丰, 王金慧, 等. 血清PLA2R抗体及IgG对特发性膜性肾病的诊断价值[J]. 江苏医药, 2022, 48(1):36-39.
|
[3] |
张新蔚, 孙爱华. 血清抗磷脂酶A2受体抗体与特发性膜性肾病相关性分析[J]. 中国卫生检验杂志, 2021, 31(1):56-59.
|
[4] |
张雪琴, 姜鸿, 杨淑芬, 等. 血清磷脂酶A2受体抗体预测利妥昔单抗治疗特发性膜性肾病疗效价值的初探[J]. 临床肾脏病杂志, 2021, 21(3):206-209.
|
[5] |
温玉, 刘嘉伟, 邱友春, 等. 血清PLA2R、IgG4检测对特发性膜性肾病的诊断中的临床价值分析[J]. 临床和实验医学杂志, 2021, 20(16):1712-1716.
|
[6] |
OSTERMANN M, BELLOMO R, BURDMANN E A, et al. Controversies in acute kidney injury:conclusions from a Kidney Disease:Improving Global Outcomes(KDIGO) Conference[J]. Kidney Int, 2020, 98(2):294-309.
DOI
URL
|
[7] |
ZHANG Q H, WU M, HU Z G, et al. Serum antibody and glomerular antigen of antiphospholipase A2 receptor in Chinese patients with idiopathic membranous nephropathy[J]. Biomed Res Int, 2020, 2020:1693710.
|
[8] |
HUANG B, WANG L, CAO Y N, et al. Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor[J]. J Allergy Clin Immunol, 2017, 139(6):1988-1990.
DOI
PMID
|
[9] |
HUANG Y, ZHOU J, ZHOU K, et al. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy:a retrospective study[J]. PeerJ, 2022, 10:e14193.
DOI
URL
|
[10] |
TOMSON C R V, CHEUNG A K, MANN J F E, et al. Management of blood pressure in patients with chronic kidney disease not receiving dialysis:synopsis of the 2021 KDIGO clinical practice guideline[J]. Ann Intern Med, 2021, 174(9):1270-1281.
DOI
URL
|
[11] |
HUANG B, ZHANG Y, WANG L, et al. Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy[J]. Kidney Blood Press Res, 2019, 44(4):848-857.
DOI
URL
|
[12] |
LI T, WU Q, YANG X, et al. Establishment and application of an immunoassay for the simultaneous detection of IgG and its subtype IgG4 autoantibodies against M-type phospholipase A2 receptor[J]. Clin Biochem, 2021, 96:49-55.
DOI
PMID
|
[13] |
饶青青, 项琼, 刘荣济, 等. 膜性肾病靶抗原研究进展[J]. 中国中西医结合肾病杂志, 2022, 23(5):462-464.
|
[14] |
杜园园, 姜雪, 王文荣, 等. IgG4水平在磷脂酶A2受体相关膜性肾病病情活动及疗效判断中的临床意义[J]. 中国医学科学院学报, 2022, 44(4):579-584.
DOI
|
[15] |
申嫒文, 林鹭, 郁胜强. IgG4升高的肾病:IgG4相关性肾病与特发性膜性肾病的研究进展[J]. 中国全科医学, 2016, 19(36):4537-4540.
|
[16] |
SUN Y, LAN P, FENG J, et al. Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels[J]. Ren Fail, 2022, 44(1):731-740.
DOI
PMID
|
[17] |
SU T, WANG H, WANG S, et al. Clinicopathological patterns and predictors of the functional restoration of immunoglobulin G4-related kidney disease:a Chinese single-center cohort study[J]. Front Med(Lausanne), 2021, 8:736098.
|
[18] |
LARSEN C P, BEGGS M L, WALKER P D, et al. Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy[J]. Am J Kidney Dis, 2014, 64(1):161-163.
DOI
PMID
|
[19] |
FERTADO J D, RUOTOLO G, NICHOLLS S J, et al. Pharmacological inhibition of CETP(cholesteryl ester transfer protein) increases HDL(high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease[J]. Arterioscler Thromb Vasc Biol, 2022, 42(2):227-237.
DOI
URL
|